Compare ZGM & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZGM | ANTX |
|---|---|---|
| Founded | 2019 | 2017 |
| Country | Macau | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.0M | 31.2M |
| IPO Year | 2025 | 2022 |
| Metric | ZGM | ANTX |
|---|---|---|
| Price | $2.08 | $1.12 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 25.0K | ★ 56.3K |
| Earning Date | 02-08-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 401.52 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $3,620,780.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.01 | ★ N/A |
| Revenue Growth | ★ 211.78 | N/A |
| 52 Week Low | $1.90 | $1.01 |
| 52 Week High | $4.51 | $1.55 |
| Indicator | ZGM | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 50.17 |
| Support Level | N/A | $1.03 |
| Resistance Level | N/A | $1.15 |
| Average True Range (ATR) | 0.00 | 0.08 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 0.00 | 50.00 |
Zenta Group Co Ltd is engaged in the provision of industrial park consultation services, business investment consultation services to clients through LIC, and sales of fintech products and services through LFT. Its industrial park consultation services are focused on the pre-development stage. Its business investment consultation services, offered through LIC, mainly focus on assisting clients to acquire stakes in specific investments, and it's normally in the form of equity ownership.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.